MiNK Therapeutics (INKT) Competitors

MiNK Therapeutics (NASDAQ:INKT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.

Which has more volatility and risk, INKT or INAB?

MiNK Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, IN8bio has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500.

Is INKT or INAB more profitable?

MiNK Therapeutics' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-220.64%
IN8bio	N/A	-147.67%	-105.00%

Do analysts rate INKT or INAB?

MiNK Therapeutics presently has a consensus price target of $9.00, indicating a potential upside of 932.47%. IN8bio has a consensus price target of $10.75, indicating a potential upside of 923.81%. Given MiNK Therapeutics' higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
IN8bio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation & earnings, INKT or INAB?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46M	-$0.66	-1.32
IN8bio	N/A	N/A	-$30.01M	-$1.01	-1.04

Does the MarketBeat Community believe in INKT or INAB?

IN8bio received 9 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. Likewise, 67.86% of users gave IN8bio an outperform vote while only 66.67% of users gave MiNK Therapeutics an outperform vote.

Company	Underperform	Outperform
MiNK Therapeutics	Outperform Votes 10 66.67%	Underperform Votes 5 33.33%
IN8bio	Outperform Votes 19 67.86%	Underperform Votes 9 32.14%

Do institutionals and insiders believe in INKT or INAB?

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 17.8% of MiNK Therapeutics shares are held by insiders. Comparatively, 33.0% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media refer more to INKT or INAB?

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 1 articles in the media. MiNK Therapeutics' average media sentiment score of 0.98 beat IN8bio's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiNK Therapeutics and IN8bio tied by winning 6 of the 12 factors compared between the two stocks.